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In membranous nephropathy, the presence of antibodies against M-type phospholipase A2
receptor is considered highly speciﬁc for idiopathic forms. However, no speciﬁc association
to  a particular clinical proﬁle has been found for such antibodies.
Objective: To assess potential differences in initial clinical proﬁle, course and prognosis of
idiopathic membranous nephropathy depending on the presence of anti-PLA2R antibodies.
Methods: Eighty-ﬁve patients with idiopathic membranous nephropathy were included (55
anti-PLA2R-positive and 30 anti-PLA2R-negative). Clinical, biochemical and pathological
variables were recorded at the time of diagnosis. Frequency of spontaneous remission, inci-
dence of response to ﬁrst-line therapy, frequency and number of recurrences, survival of
renal  function free from renal replacement therapy, survival of renal function free from
chronic renal insufﬁciency and frequency of occurrence of malignant, infectious or autoim-
mune  diseases during follow-up were recorded.
Results: At the time of diagnosis, anti-PLA2R-negative patients were signiﬁcantly older andhad  a higher frequency of spontaneous remission. No differences were noted in the response
to  ﬁrst-line treatment, frequency and number of recurrences, survival of renal function
free from renal replacement therapy, or survival of renal function free from chronic renal
insufﬁciency.
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Conclusions: Anti-PLA2R-negative patients with idiopathic membranous nephropathy were
older and experienced spontaneous remission more often than anti-PLA2R-positive
patients. No differences in terms of treatment response, recurrences, and ﬁnal prognosis
were observed between both groups of patients.
© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de
Nefrología. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Características  clínicas,  evolución  y  pronóstico  de  la  nefropatía
membranosa  idiopática  en  función  de  la  presencia  de  anticuerpos  contra
el  receptor  tipo  M  de  la  fosfolipasa  A2
Palabras clave:
Nefropatía membranosa
idiopática
Anticuerpos anti-PLA2R
Síndrome nefrótico
Pronóstico
r  e  s  u  m  e  n
En la nefropatía membranosa (NM), la presencia de anticuerpos antirreceptor tipo M de
fosfolipasa A2 se considera altamente especíﬁca para las formas idiopáticas, pero no se
ha  demostrado que la presencia de dichos anticuerpos se asocie a un determinado perﬁl
clínico.
Objetivo: Analizar si existe alguna diferencia en cuanto al perﬁl clínico inicial, evolución y
pronóstico entre pacientes con NM idiopática en función de la presencia de anticuerpos
anti-PLA2R.
Métodos: Se estudió a 85 enfermos con NM idiopática, 55 eran anti-PLA2R positivos y
30  negativos. Se registraron las variables clínicas, bioquímicas y anatomopatológicas al
momento del diagnóstico, la frecuencia de remisión espontánea, la incidencia de respuesta
al  tratamiento de primera línea, la frecuencia y número de recidivas, la supervivencia de la
función renal libre de tratamiento sustitutivo renal, la supervivencia de la función renal libre
de  insuﬁciencia renal crónica y la frecuencia de aparición de enfermedades neoplásicas,
infecciosas o autoinmunes durante el seguimiento.
Resultados: Al momento del diagnóstico, los enfermos anti-PLA2R negativos presentaron
signiﬁcativamente mayor edad y frecuencia de remisión espontánea. No se apreciaron difer-
encias en la respuesta al tratamiento de primera línea, frecuencia ni número de recidivas,
supervivencia de la función renal libre de tratamiento sustitutivo renal ni supervivencia de
función renal libre de insuﬁciencia renal crónica.
Conclusiones: Los enfermos con NM idiopática anti-PLA2R negativos presentaron mayor edad,
menor ﬁltrado glomerular inicial y mayor frecuencia de remisión espontánea que los enfer-
mos  anti-PLA2R positivos. Sin embargo, entre ambos grupos de enfermos, no se observaron
diferencias en cuanto a la respuesta y al tratamiento, aparición de recidivas ni pronóstico
ﬁnal.
©  2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española
de  Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-NDIntroduction
Membranous nephropathy (MN) is the leading cause of
nephrotic syndrome among adults.1 It is clinically classi-
ﬁed into idiopathic (IMN) or secondary, depending on the
identiﬁcation of an aetiology. When clinical or biochemi-
cal data suggesting a speciﬁc cause are not available, their
differentiation based on the sole use of data derived from
renal biopsies can be challenging.2,3 Several recent studies
have reported that nearly 70% of IMN  cases are associated
with the presence of antibodies against M-type phospholi-
pase A2 receptor (anti-PLA2R).4 The likelihood of spontaneous
remission5 (SR) and treatment response is associated with
antibody titres at diagnosis.5–10 Nonetheless, the presence
of anti-PLA2R antibodies in IMN  patients was not shown to
be associated with a particular clinical proﬁle or to result(http://creativecommons.org/licenses/by-nc-nd/4.0/).
in differences regarding clinical course, treatment response,
or long-term prognosis. Also, and despite the majority of
trials agreeing that the presence of anti-PLA2R antibod-
ies is highly speciﬁc for idiopathic forms of MN,4,5,7,12–14
the said antibodies have been reported to be consistent
with other potential aetiologies,15 and around 30% of IMN
patients are anti-PLA2R negative. Antibodies against other
podocyte antigens whose clinical correlation is still under
investigation have been described in this last group of
patients,16–19 which is why the potential identiﬁcation of
secondary aetiologies over time remains largely uncertain.
Yet, given that most trials had a transversal design, little
information is available on the diagnosis of potential aeti-
ologies of MN over time in anti-PLA2R positive and negative
patients.
The purpose of this study is to assess potential differences
in initial clinical proﬁle, clinical course, treatment response,
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r prognosis of IMN  based on the presence or absence of anti-
LA2R antibodies.
atients  and  methods
e  conducted a retrospective study involving patients over 18
ears old with a renal biopsy diagnosis of nephrotic syndrome
econdary to MN between 1985 and 2009, who complied with
he following criteria: (1) absence of an aetiology of MN, fol-
owing a protocol study which ruled out neoplastic, systemic,
nd infectious diseases or exposure to drugs at diagnosis, and
2) available renal tissue samples for immunohistochemistry
r serum samples at diagnosis for the measurement of circu-
ating anti-PLA2R antibodies.
Clinical, demographic, and biochemical variables were
ecorded at the time of diagnosis and during follow-up.
erum creatinine was determined using a compensated IDMS-
raceable method (Hitachi Modular P-800 Roche Diagnostics,
erlin, Germany). The estimated glomerular ﬁltration rate
eGFR) was measured using CKD-EPI.20
Patients were classiﬁed into two groups based on the
resence or absence of anti-PLA2R antibodies shown by
mmunohistochemistry in the renal biopsy or by the evidence
f high circulating levels at diagnosis.
The percentage of glomerular sclerosis was determined
n all renal biopsies, together with the extent of intersti-
ial ﬁbrotic lesions, which was classiﬁed into four categories:
: absent; grade I: ≤25%; grade II: 26–50%, and grade III:
50%. For biopsies where parafﬁn-embedded specimens were
vailable, 5 m sections were made for anti-PLA2R anti-
ody staining (HPA012657 Sigma–Aldrich Co. LLC, Munich,
ermany) by immunohistochemistry (IHC) based on the pre-
iously described technique.13
Circulating anti-PLA2R antibodies were measured
sing ELISA (Euroimmun, Lübeck, Germany; linearity:
–1500 RU/mL; lowest detection limit: 0.6 RU/mL). Titres
20 RU/mL were considered positive.
ollow-up  and  controls
ollowing diagnosis, all patients underwent follow-up and
bservation prior to initiation of immunosuppression, dur-
ng which symptomatic treatment was prescribed, including a
ow-sodium diet, and patients diagnosed from 1994 onwards
eceived angiotensin receptor blockers and statins. Patients
ho  did not achieve SR following observation received
mmunosuppressants.
utcome  measures
1) Percentage and incidence of SR. (2) Incidence of response
total or partial remission) in the 12 months following ﬁrst-line
reatment initiation. (3) Time between treatment initiation
nd remission. (4) Percentage of patients experiencing recurr-
nces, incidence and total number of recurrences. (5) Survival
f renal function free from renal replacement therapy at
he end of follow-up. (6) Survival of renal function free
rom chronic renal failure (CRF) at the end of follow-up.(5):479–486 481
(7) Frequency of development of de novo neoplasia or other
potential causes for MN during observation.
Deﬁnitions
Complete remission: proteinuria <0.3 g/day in two consec-
utive controls. Partial remission: proteinuria <3.5 g/day, and
>0.3 g/day in two consecutive controls. SR: complete or partial
remission without immunosuppressants. Recurrence: pro-
teinuria >3.5 g/day associated with hypoalbuminaemia in two
consecutive controls following treatment suppression. CRF:
eGFR <60 mL/min/1.73 m2.
The trial complied with the Helsinki Declaration parame-
ters and was approved by the centre’s Bioethics Committee.
Statistical  analysis
Results are summarised as mean and typical deviation for
normal distribution variables or as median and interquartile
ranges for skewed distribution variables. Mean differences
between study groups were analysed using Student’s t test
for independent data or Mann–Whitney U test. A variance
analysis (ANOVA) was used for differences between more
than two means. Ratio differences were analysed using Chi-
square test or Fisher exact test. Independent predictors of
SR were analysed using a stepwise logistic regression model.
The discriminatory capacity was analysed using area under
the ROC curve, and risk calibration was assessed through the
Hosmer–Lemeshow test.21 Independent variables associated
with remission rates following treatment and overall survival
of renal function at the end of follow-up were analysed using
Kaplan–Meier estimates with the log-rank test for group dif-
ferentiation, followed by Cox regression analysis to identify
independent predictors. All p < 0.05 values were considered
statistically signiﬁcant. The statistical program SPSS v. 20.0
was used.
Results
Table 1 summarises the clinical, biochemical, and patholog-
ical characteristics of the 85 patients enrolled in the study,
based on the presence or absence of anti-PLA2R antibodies.
The anti-PLA2R positive study group consisted of 55 patients:
15 (27.1%) had high titres of anti-PLA2R antibodies detected
through ELISA, while immunohistochemistry was not possible
owing to the absence of sufﬁcient biopsy material; glomerular
deposition was detected in 10 patients (17.6%) by immuno-
histochemistry, though no serum sample was available to
determine antibody titres at diagnosis, and 30 (54.5%) patients
had positive antibodies in both serum and renal biopsy.
Anti-PLA2R positive patients were signiﬁcantly younger (p:
0.019), had lower creatinine levels and higher eGFR compared
to anti-PLA2R negative patients (p: 0.033 and 0.027, respec-
tively). When analysing baseline creatinine distribution in the
two groups, three anti-PLA2R negative patients had excep-
tionally high creatinine levels compared to the rest of the
group. No signiﬁcant differences were observed between anti-
PLA2R positive and negative patients after these patients were
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Table 1 – Baseline clinical and pathological features of patients based on the presence or absence of anti-PLA2R
antibodies.
Anti-PLA2R
Positive Negative p
Patients % (n) 64.7  (55) 35.3 (30)
Gender % (n)
M 65.5 (36) 83.3 (25) 0.08
F 34.5 (19) 16.7 (5)
Age (years) 49 ± 16.4 57.8 ± 15.7 0.019
Cholesterol total (mg/dL) 340.2 ± 85.9 326.5 ± 68.4 0.461
Albumin (mg/dL) 2.39 ± 0.56 2.54 ± 0.68 0.282
Creatinine (mg/dL) 1.03 ± 0.3 1.48 ± 1.08 0.033
Proteinuria (g/24 h) 10.6 ± 4.6 8.6 ± 4.2 0.064
Glomerular ﬁltration (mL/min/1.73 m2) 81.8 ± 23.65 69.11 ± 27.28 0.027
Diabetes % (n) 7.3 (4) 3.3 (1) 0.46
High blood pressure % (n) 34.5 (19) 20 (6) 0.16
Angiotensin blockers ii % (n) 87.2 (48) 86.6 (26) 0.937
Spontaneous remission % (n) 14.5 (8) 40 (12) 0.015
First-line treatment (n) (47) (18)
Corticosteroids 12.8 (6) 22.2 (4)
Alkylating agents 25.5 (12) 11.1 (2) 0.356
Calcineurin inhibitors 61.7 (29) 66.7 (12)
Glomerular sclerosis 14.2 ± 19.1 15.9 ± 32.2 0.812
Fibrosis (n) (36) (16)
Absent % (n) 27.8 (10) 31.2 (5)
Grade I 47.2 (17) 43.8 (7)
Grade II 19.4 (7) 12.5 (2) 0.78
Grade III 5.6 (2) 12.5 (2)Only p values under 0.05 are highlighted in bold.
excluded from analysis. No differences were observed in the
remaining clinical and pathological variables under study.
Mean observation time prior to treatment was 8.34 ± 6.25
months (median: 6.5; P25: 6 and P75: 9 months). A total of 20
patients (23.5%) achieved SR. The incidence of SR was of 0.041
episodes/patient/month. In the univariate analysis, SR was
associated with lower proteinuria at baseline (6.84 ± 3.10 vs
10.88 ± 4.53 g/24 h; p < 0.001), higher albuminaemia (2.82 ± 0.65
vs 2.32 ± 0.54 g/dL; p: 0.001), and anti-PLA2R negativity (SR:
12/30 [40%] anti-PLA2R negative vs 8/55 [14.5%] in anti-PLA2R
positive; p: 0.015). In the multivariate analysis, proteinuria and
anti-PLA2R negativity were the single SR-independent pre-
dictors (Table 2). No signiﬁcant differences were reported in
time to SR among anti-PLA2R positive and negative patients
(7.10 ± 2.60 vs 7.28 ± 2.42 months; p: 0.893). No association
between baseline antibody titres and frequency of SR was
observed in the 45 patients with anti-PLA2R antibody titre
values.
Immunosuppressants were administered to the 65 patients
who  did not achieve SR. Ten patients (15.6%) received
prednisone alone, 14 (21.8%) received alkylating drugs
(cyclophosphamide or chlorambucil) in combination with cor-
ticosteroids for 6 months, and 41 (63%) were treated with
calcineurin inhibitors (cyclosporine or tacrolimus) for at least
6 months and a maximum of 12 months. No signiﬁcant differ-
ences were reported in terms of kind of drug used as ﬁrst-line
therapy among anti-PLA2R positive and negative patients.
Three (30%) of the 10 patients receiving corticosteroids aloneachieved partial remission in the 12 months following treat-
ment initiation. Two of them experienced recurrence. One
received treatment with cyclophosphamide and achieved par-
tial remission; the other received corticosteroids alone again
and achieved partial remission. The remaining seven patients
only received symptomatic treatment. At the end of follow-up,
6 of the 10 patients treated with corticosteroids (60%) devel-
oped CRF, but none progressed to stage V CRD.
After exclusion of patients receiving steroids alone
from the analysis of treatment response, 34/55 patients
(61.81%) achieved partial or total remission and 21/55
(38.18%) did not achieve a response. Table 3 summarises
the clinical, biochemical, and pathological characteristics
of patients based on the assessment of response to ﬁrst-
line treatment at 12 months from baseline. Remission was
associated with lower baseline proteinuria. No signiﬁcant
association was reported between any of the remaining
variables and baseline treatment response in the ﬁrst
12 months. The incidence of remission in the ﬁrst 12
months was similar among anti-PLA2R positive and negative
patients (Fig. 1; p: 0.780). No differences were noted among
patients receiving alkylating drugs or calcineurin inhibitors
(p: 0.40).
Alternative immunosuppressants were administered to
the 21 non-responders to ﬁrst-line treatment. A total of
nine (90.47%) patients received calcineurin inhibitors and two
(9.52%) patients received calcineurin inhibitor plus rituximab,
with total or partial remission observed in all cases.
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Table 2 – Independent variables associated with spontaneous remission.
B Wald OR IC (95%) p
Age 0.017 0.469 1.01 0.97–1.06 0.493
Proteinuria −3.241 8.28 0.802 0.69–0.93 0.004
Anti-PLA2R negativity 1.49 5.41 4.46 1.26–15.73 0.020
Table 3 – Baseline clinical and pathological features of patients based on ﬁrst-line treatment response.
Response No response p
Patients % (n) 61.81  (34) 38.18 (21)
Gender % (n)
M 64.7 (22) 76.2 (16) 0.50
F 35.3 (12) 23.8 (5)
Age (years) 50.7 ± 14.70 48.8 ± 18.79 0.69
Total cholesterol (mg/dL) 355.1 ± 82.09 346.5 ± 67.56 0.69
Albumin (mg/dL) 2.35 ± 0.58 2.18 ± 0.47 0.27
Creatinine (mg/dL) 1.09 ± 0.60 1.36 ± 0.96 0.19
eGFR (mL/min) 82.24 ± 26.89 71.21 ± 25.8 0.09
Proteinuria (g/24 h) 11 ± 4.38 13.67 ± 2.73 0.018
Anti-PLA2R
Positive % (n) 79.41 (27) 66.7 (14) 0.37
Negative 20.6 (7) 33.3 (7)
Glomerular sclerosis 13 ± 17.6 10.99 ± 21.7 0.74
Fibrosis (n) (20) (15)
Absent % (n) 25 (5) 33.3 (5)
Grade I 55 (11) 53.3 (8) 0.80
Grade II 20 (4) 13.3 (2)
Grade III 0 (0) 0 (0)
P
p
p
p
1
0
e
r
f
F
t
pTotal cholesterol: mean total cholesterolaemia.
Mean follow-up was 75.3 ± 49 months (median: 62; P25: 39;
75: 105 months). During this time, 32 of the 54 remitting
atients (59.2%) experienced recurrence, including 6 of the 20
atients achieving SR (30%) and 26 of the 34 patients with
ost-treatment remission (76.4%). Mean recurrences were of
.59 ± 1.25 (interval 0–5). The incidence of recurrences was
.033 episodes/patient/year. No statistically signiﬁcant differ-
nces were reported between the frequency or incidence of
ecurrences and any of the study variables. No signiﬁcant dif-
erences were reported in the number of recurrences between
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ig. 1 – Incidence of remission in the ﬁrst 12 months of
reatment based on anti-PLA2R positivity. Log-rank: 0.141;
: 0.708.anti-PLA2R positive (1.32 ± 0.56) and negative (1.94 ± 1.74; p:
0.07) patients. The number of recurrences between patients
receiving calcineurin inhibitors and patients receiving alkyl-
ating agents as ﬁrst-line treatment was not signiﬁcant either.
Twenty-six (81.2%) patients experiencing recurrence
received calcineurin inhibitors and six (18.8%) received
alkylating agents, achieving total or partial remission of the
nephrotic syndrome in 93.7% of cases (n: 30). Calcineurin
inhibitors were continued for a mean time of 47.8 ± 20.8
months (range 22–83) in ten patients experiencing more  than
three recurrences. These patients were subsequently treated
with rituximab, achieving calcineurin inhibitor treatment
suppression for all cases.22
At the end of follow-up, survival of renal function free from
renal replacement therapy was 95.2%. Fig. 2 illustrates the sur-
vival of renal function free from renal replacement based on
the presence or absence of anti-PLA2R antibodies. No signiﬁ-
cant differences were seen between groups. CRF-free survival
of renal function was 70%. Table 4 summarises the variables
associated with the development of CRF in the univariate (A)
and multivariate (B) analyses. In this group, age, baseline renal
function, and evidence of remission within the ﬁrst year of
immunosuppressive treatment were the single independent
predictors of RF development.
Two patients, one anti-PLA2R positive, the other anti-PLA2R
negative, developed de novo neoplasia during follow-up, both
consistent with prostate adenocarcinomas. The time between
diagnosis of MN and neoplasia was 3.5 years. An anti-PLA2R
negative male patient under partial remission died during
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Table 4 – CRD-associated variables in the univariate (A) and multivariate (B) analysis.
(A) CRF Without CRF p
Patient % (n) 31.08 (23) 68.91 (51)
Age 62.65 ± 17.052 47.12 ± 13.85 <0.001
Baseline eGFR (mL/min) 59.91 ± 24.8 68.19 ± 21.12 <0.001
ACE treatment % (n) 82.6  (19) 100  (51) 0.008
HBP % 56.5  (13) 23.5  (12) 0.008
Glomerular sclerosis % 23.05 ± 28.63 8.78 ± 15.97 0.039
Fibrosis (n) (17) (27)
Absent % (n) 11.8 (2) 40.7 (11)
Grade I 35.3 (6) 51.9 (14) <0.001
Grade II 41.2 (7) 7.4 (2)
Grade III 11.8 (2) 0 (0)
Remission in the ﬁrst 12 months
following start of treatment % (n)
30.8  (4) 73.2 (30) 0.009
(B) B Wald OR CI (95%) p
Age 0.083 6.172 1.087 1.018–1.161 0.013
Baseline eGFR −0.05 7.558 0.95 0.918–0.986 0.006
Remission in the 12 months from start −2.90  4.37 0.055 0.004–0.834 0.036of immuno-suppression % (n)
follow-up from an acute coronary syndrome 48 months after
diagnosis of MN.
Discussion
Our data reveal that IMN  patients show similar biochemi-
cal and pathological proﬁle at diagnosis – except for age –
irrespective of the presence of anti-PLA2R antibodies. The
likelihood of SR was signiﬁcantly higher among anti-PLA2R
negative patients after adjusting for proteinuria and base-
line renal function. These data are consistent with those in
a number of recent studies,14 though in disagreement with
others7,11, and show no signiﬁcant differences between anti-
PLA2R positive and negative patients. The frequency of SR was
slightly lower than that described in previous trials23–25 and,
unlike these previous reports, no association was identiﬁed
1.0
0.8
Cu
m
ul
at
ive
 s
ur
viv
al
0.4
0.6
0.2
0.0
.00 50.00 100.00 150.00 200.00
Time tracking monthsp: 0.6
0
0-censored
1
1-censored
AntiPLA2R
Fig. 2 – Renal survival in anti-PLA2R positive and negative
patients. p: 0.6.between renin-angiotensin-aldosterone blockers and baseline
renal function. The absence of a link to the use of angiotensin
II blockers may be explained by the fact that most patients
diagnosed before 1994 had not been systematically prescribed
with this type of drug following diagnosis. In addition, this
fact could also partly account for the lower frequency of SR
as reported in our cohort. Additionally, given that the fre-
quency of SR increases over time,25 longer observation periods
might have resulted in increased frequency. The absence of a
link to baseline renal function may be explained by normal
renal function of most patients at baseline. Mean baseline
creatinine and eGFR were lower among anti-PLA2R negative
patients. The possibility of ST would be expected to be lower
in this group. However, this was not observed in the univariate
and multivariate analyses. The reason here lies in the fact that
three patients from this group had extreme creatinine levels,
which inﬂuenced the size of the mean values. Following exclu-
sion from analysis, and after the comparison, no signiﬁcant
differences were observed. Anti-PLA2R negativity behaved as
an independent variable and was associated with a higher
probability of SR. These results may suggest that observation
time prior to active immunosuppression can be extended in
anti-PLA2R negative IMN patients, provided there is no exac-
erbation of renal function or proteinuria. Nevertheless, this
ﬁnding must be conﬁrmed by other trials before the suggestion
can be considered conclusive.
Post-treatment outcome, ﬁrst-line treatment response,
recurrences, and renal function survival rate were sim-
ilar between anti-PLA2R positive and negative patients.
These data are consistent with other recent studies already
published.7,9,10,23 The presence of anti-PLA2R antibodies in
the multivariate analysis was not an independent predictor
of long-term survival of renal function.One last ﬁnding from our data is that no potential IMN-
related diseases were diagnosed after extended follow-up in
any of the patients initially diagnosed with IMN,  irrespective
of the presence or absence of anti-PLA2R antibodies, showing
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hat the probability of a secondary aetiology is low, in both
nti-PLA2R positive and negative patients, unless otherwise
evealed at diagnosis.
Our study is based on a retrospective cohort, and as such
aces certain limitations and may be biased as a result of
he inﬂuence of unmeasured variables. First, although the
resence of anti-PLA2R antibodies in all patients classiﬁed as
aving positive anti-PLA2R antibodies is certain, they should
ave been identiﬁed through the combination of immuno-
istochemical and serological techniques, as the two sets of
nformation were not concurrently available in some patients.
onsequently, only partial analysis of the association between
nti-PLA2R titres and the probability of SR was possible, thus
ffecting the statistical power of the results. Second, the
tudy includes patients diagnosed and treated over a very
ong period, when study protocols, follow-up, and treatments
iffered and were not always governed by clearly deﬁned
uidelines. Although an analysis consistent with real clinical
ractice at each time point is possible, comparison of the data
s therefore difﬁcult, which might explain some of the differ-
nces found with other groups of patients in the literature,
here decisions were made based on protocol- or guideline-
eﬁned criteria. Of note, 10 of the 64 patients without SR
eceived corticosteroids alone. All had been treated before
his treatment was shown in various studies to be ineffective
n changing the clinical course of IMN.  For this reason their
rogress is described separately, following exclusion from the
fﬁcacy analysis in terms of ﬁrst-line treatment response.
In conclusion, our data show that patients with IMN
ssociated to anti-PLA2R antibodies are older at diagnosis
nd their frequency of SR is higher than that of anti-PLA2R
ositive patients. However, no differences between the two
roups of patients were found in terms of response to ﬁrst-
ine treatment, time to remission, frequency and number of
ecurrences, diagnosis of potential MN-related causes, and
rognosis following observation.
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